================================================================================


                       SECURITIES AND EXCHANGE COMMISSION

                              Washington, D.C. 20549

                                     FORM 8-K

                                  CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): June 25, 2002

                            BioMarin Pharmaceutical Inc.
                (Exact name of registrant as specified in its charter)


         Delaware                       000-26727                 68-0397820
(State or other jurisdiction of        (Commission              (IRS Employer
 incorporation or organization)        File Number)          Identification No.)


371 Bel Marin Keys Boulevard, Suite 210, Novato, California              94949
(Address of principal executive offices)                              (Zip Code)


Registrant's telephone number, including area code:           (415) 884-6700


                                 Not Applicable
          ----------------------------------------------------------------
           (Former name or former address, if changed since last report)
================================================================================

================================================================================









Item 5.  Other Events.

     On June 25, 2002, BioMarin Pharmaceutical Inc. (the "Registrant") announced
findings  from the Phase 1 trial and the  preliminary  findings  of the  related
extension study of its product candidate  Aryplase(TM).  The Registrant's  press
release issued on June 25, 2002 is attached hereto as Exhibit 99.1.

Item 7.       Financial Statements, Pro Forma Financial Statements and Exhibits.


         (a)  Financial Statements of Business Acquired.

              Not Applicable.

         (b)  Pro Forma Financial Information.

              Not Applicable.

         (c)  Exhibits.

              Exhibit 99.1      Press Release of the Registrant dated June 25,
                                2002









                                  SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                         BioMarin Pharmaceutical Inc.,
                         a Delaware corporation


Date: June 25, 2002                 By: /s/ Fredric D. Price
                                        --------------------
                                            Fredric D. Price
                                            Chairman and Chief Executive Officer



                                EXHIBIT INDEX

Exhibit No.                Description

Exhibit 99.1               Press Release of the Registrant dated June 25, 2002